Latest From Pharmstandard OJSC
Lilly is the latest established biopharma to license Halozyme's EXTENZE subcutaneous delivery technology. Mallinckrodt pays $175m up front to The Medicines Co. for a trio of topical hemostasis drugs.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in August 2015.
Depomed deems increased buyout offer from Horizon as insufficient, possibly leaving Horizon to consider alternative acquisitions. Valeant will pay $1bn to acquire Sprout and its just approved female sexual desire disorder drug Addyi.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging life science companies that have received venture funding, including companies within the In Vitro Diagnostics, Medical Devices, and Pharmaceuticals sectors. This month’s column covers deals announced March through April 2015.
- Therapeutic Areas
- OJSC Pharmstandard
- Biovit LLC
- Eastern Europe
- Parent & Subsidiaries
- Pharmstandard OJSC
- Senior Management
Vladimir Chupikov , CEO
Marina Markova , CFO
- Contact Info
Phone: 495 970 00 30
5 ‘B’ Likhachevsky proezd
Dolgoprudny, Moscow Region, 141700
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.